Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 7
2004 5
2005 10
2006 9
2007 2
2008 5
2011 3
2012 3
2013 5
2014 5
2015 5
2016 3
2017 2
2018 2
2019 2
2020 1
2022 4
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4+ and CD8+ memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients.
Coulon PG, Prakash S, Dhanushkodi NR, Srivastava R, Zayou L, Tifrea DF, Edwards RA, Figueroa CJ, Schubl SD, Hsieh L, Nesburn AB, Kuppermann BD, Bahraoui E, Vahed H, Gil D, Jones TM, Ulmer JB, BenMohamed L. Coulon PG, et al. Among authors: ulmer jb. Front Immunol. 2024 Mar 28;15:1343716. doi: 10.3389/fimmu.2024.1343716. eCollection 2024. Front Immunol. 2024. PMID: 38605956 Free PMC article.
A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model.
Prakash S, Dhanushkodi NR, Singer M, Quadiri A, Zayou L, Vahed H, Coulon PG, Ibraim IC, Tafoya C, Hitchcock L, Landucci G, Forthal DN, El Babsiri A, Tifrea DF, Figueroa CJ, Nesburn AB, Kuppermann BD, Gil D, Jones TM, Ulmer JB, BenMohamed L. Prakash S, et al. Among authors: ulmer jb. bioRxiv [Preprint]. 2024 Feb 15:2024.02.14.580225. doi: 10.1101/2024.02.14.580225. bioRxiv. 2024. PMID: 38405942 Free PMC article. Preprint.
Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern.
Prakash S, Dhanushkodi NR, Zayou L, Ibraim IC, Quadiri A, Coulon PG, Tifrea DF, Suzer B, Shaik AM, Chilukuri A, Edwards RA, Singer M, Vahed H, Nesburn AB, Kuppermann BD, Ulmer JB, Gil D, Jones TM, BenMohamed L. Prakash S, et al. Among authors: ulmer jb. Front Immunol. 2024 Jan 22;15:1328905. doi: 10.3389/fimmu.2024.1328905. eCollection 2024. Front Immunol. 2024. PMID: 38318166 Free PMC article.
A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4+ and CD8+ T cells and enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2 infection.
Zayou L, Prakash S, Dhanushkodi NR, Quadiri A, Ibraim IC, Singer M, Salem A, Shaik AM, Suzer B, Chilukuri A, Tran J, Nguyen PC, Sun M, Hormi-Carver KK, Belmouden A, Vahed H, Gil D, Ulmer JB, BenMohamed L. Zayou L, et al. Among authors: ulmer jb. J Virol. 2023 Dec 21;97(12):e0109623. doi: 10.1128/jvi.01096-23. Epub 2023 Dec 1. J Virol. 2023. PMID: 38038432 Free PMC article.
Cross-Protection Induced by Highly Conserved Human B, CD4+, and CD8+ T Cell Epitopes-Based Coronavirus Vaccine Against Severe Infection, Disease, and Death Caused by Multiple SARS-CoV-2 Variants of Concern.
Prakash S, Dhanushkodi NR, Zayou L, Ibraim IC, Quadiri A, Coulon PG, Tifrea DF, Suzler B, Amin M, Chilukuri A, Edwards RA, Vahed H, Nesburn AB, Kuppermann BD, Ulmer JB, Gil D, Jones TM, BenMohamed L. Prakash S, et al. Among authors: ulmer jb. bioRxiv [Preprint]. 2023 May 24:2023.05.24.541850. doi: 10.1101/2023.05.24.541850. bioRxiv. 2023. PMID: 37292861 Free PMC article. Updated. Preprint.
Vaccines on demand, part II: future reality.
Geall AJ, Kis Z, Ulmer JB. Geall AJ, et al. Among authors: ulmer jb. Expert Opin Drug Discov. 2023 Feb;18(2):119-127. doi: 10.1080/17460441.2022.2147501. Epub 2022 Nov 23. Expert Opin Drug Discov. 2023. PMID: 36384351 Review.
A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.
Maruggi G, Mallett CP, Westerbeck JW, Chen T, Lofano G, Friedrich K, Qu L, Sun JT, McAuliffe J, Kanitkar A, Arrildt KT, Wang KF, McBee I, McCoy D, Terry R, Rowles A, Abrahim MA, Ringenberg MA, Gains MJ, Spickler C, Xie X, Zou J, Shi PY, Dutt T, Henao-Tamayo M, Ragan I, Bowen RA, Johnson R, Nuti S, Luisi K, Ulmer JB, Steff AM, Jalah R, Bertholet S, Stokes AH, Yu D. Maruggi G, et al. Among authors: ulmer jb. Mol Ther. 2022 May 4;30(5):1897-1912. doi: 10.1016/j.ymthe.2022.01.001. Epub 2022 Jan 3. Mol Ther. 2022. PMID: 34990810 Free PMC article. Clinical Trial.
Antibody-guided structure-based vaccines.
Kwong PD, DeKosky BJ, Ulmer JB. Kwong PD, et al. Among authors: ulmer jb. Semin Immunol. 2020 Aug;50:101428. doi: 10.1016/j.smim.2020.101428. Epub 2020 Nov 24. Semin Immunol. 2020. PMID: 33246736 Review.
77 results